Insys Therapeutics Overview
- Year Founded
-
1990
- Status
-
Acquired/Merged
- Employees
-
226
- Latest Deal Type
-
M&A
- Financing Rounds
-
4
- Investments
-
2
Insys Therapeutics General Information
Description
Developer of biopharmaceutical products based in Chandler, Arizona. The company develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients' quality of life.
Contact Information
Website
www.insysrx.comCorporate Office
- 1333 South Spectrum Boulevard
- Suite 100
- Chandler, AZ 85286
- United States
Corporate Office
- 1333 South Spectrum Boulevard
- Suite 100
- Chandler, AZ 85286
- United States
Insys Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Insys Therapeutics Comparisons
Industry
Financing
Details
Insys Therapeutics Competitors (8)
One of Insys Therapeutics’s 8 competitors is Novartis, a Corporation company based in Basel, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | ||||
| Sanofi | Corporation | Gentilly, France | ||||
| Nevian Lifescience | Corporate Backed or Acquired | Dhaka, Bangladesh | ||||
| Santhera Pharmaceuticals Holding | Formerly VC-backed | Pratteln, Switzerland | ||||
| Evonile Pharma | Private Equity-Backed | Mumbai, India |
Insys Therapeutics Patents
Insys Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10039710-B2 | Epinephrine spray formulations | Active | 18-Sep-2015 | ||
| US-10617637-B2 | Epinephrine spray formulations | Active | 18-Sep-2015 | ||
| US-10966925-B2 | Epinephrine spray formulations | Active | 18-Sep-2015 | ||
| US-10973781-B2 | Epinephrine spray formulations | Active | 18-Sep-2015 | ||
| US-11517525-B2 | Epinephrine spray formulations | Active | 18-Sep-2015 | A61K9/08 |
Insys Therapeutics Signals
Insys Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Insys Therapeutics Investments & Acquisitions (2)
Insys Therapeutics’s most recent deal was a Later Stage VC with Utonomy for . The deal was made on 02-Oct-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Utonomy | 02-Oct-2022 | Later Stage VC | Electronic Equipment and Instruments | ||
| NeoPharm | 09-Nov-2010 | Merger/Acquisition | Drug Discovery |
Insys Therapeutics FAQs
-
When was Insys Therapeutics founded?
Insys Therapeutics was founded in 1990.
-
Where is Insys Therapeutics headquartered?
Insys Therapeutics is headquartered in Chandler, AZ.
-
What is the size of Insys Therapeutics?
Insys Therapeutics has 226 total employees.
-
What industry is Insys Therapeutics in?
Insys Therapeutics’s primary industry is Pharmaceuticals.
-
Is Insys Therapeutics a private or public company?
Insys Therapeutics is a Private company.
-
What is Insys Therapeutics’s current revenue?
The current revenue for Insys Therapeutics is .
-
How much funding has Insys Therapeutics raised over time?
Insys Therapeutics has raised $29.8M.
-
Who are Insys Therapeutics’s investors?
NeoPharm has invested in Insys Therapeutics.
-
Who are Insys Therapeutics’s competitors?
Novartis, Sanofi, Nevian Lifescience, Santhera Pharmaceuticals Holding, and Evonile Pharma are some of the 8 competitors of Insys Therapeutics.
-
When was Insys Therapeutics acquired?
Insys Therapeutics was acquired on 01-Jan-2022.
-
Who acquired Insys Therapeutics?
Insys Therapeutics was acquired by Pernix Manufacturing.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process